AID  Vol.10 No.3 , December 2020
Biological Disruptive Therapies as Counter Measures for Unpredictable Biological Insults, a Case for Successful Treatment of COVID-19
Abstract: Treatment of patients with severe COVID-19, is challenging specifically when a patient carries high risk of mortality, such as old age, immune suppression or cancer. Also a patient who manifests the disease with severe symptoms, such as hypoxia, requiring supplemental oxygenation, or artificial ventilation has a poor prognosis. Here we review the scientific rationale used to design a very promising therapy based on existing literature, but in significantly different method and protocols, used to treat cases of severe COVID-19, and we conclude that although the effort on drug development has been enormous, but as of today, we do not have a therapy with specific characteristics as this protocol, to be used safely in human and yet potentially meet the expectations we would have for a so called “effective therapy”. Further clinical trials are needed to support this hypothesis and generate further hypothesis to prove the concept in larger cohort of patients.
Cite this paper: Nezami, M. and Yamamoto, V. (2020) Biological Disruptive Therapies as Counter Measures for Unpredictable Biological Insults, a Case for Successful Treatment of COVID-19. Advances in Infectious Diseases, 10, 175-183. doi: 10.4236/aid.2020.103018.

[1]   Dai, M.Y., et al. (2020) Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multi-Center Study during the COVID-19 Outbreak. Cancer Discovery, 10, 783-791.

[2]   Stenger, M. (2020) Results of a COVID-19 and Cancer Consortium (CCC19) Cohort Study—The ASCO Post.

[3]   Chen, N.S., Zhou, M., Dong, X., Qu, J.M., Gong, F.Y., Han, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet, 395, 507-513.

[4]   Bultmann, H. and Brandt, C.R. (2002) Peptides Containing Membrane-Transiting Motifs Inhibit Virus Entry. The Journal of Biological Chemistry, 277, 36018-36023.

[5]   Bultmann, H., Busse, J.S. and Brandt, C.R. (2001) Modified FGF4 Signal Peptide Inhibits Entry of Herpes Simplex Virus Type 1. Journal of Virology, 75, 2634-2645.

[6]   Dragic, T., Trkola, A., Thompson, D.A., Cormier, E.G., Kajumo, F.A., Maxwell, E., Lin, S.W., Ying, W., Smith, S.O., Sakmar, T.P. and Moore, J.P. (2000) A Binding Pocket for a Small Molecule Inhibitor of HIV-1 Entry within the Transmembrane Helices of CCR5. Proceedings of the National Academy of Sciences of the United States of America, 97, 5639-5644.

[7]   Este, J.A. (2003) Virus Entry as a Target for Anti-HIV Intervention. Current Medicinal Chemistry, 10, 1617-1632.

[8]   Agelidis, A.M. and Shukla, D. (2015) Cell Entry Mechanisms of HSV: What We Have Learned in Recent Years. Future Virology, 10, 1145-1154.

[9]   Guan, Y., Zheng, B.J., He, Y.Q., Liu, X.L., Zhuang, Z.X., Cheung, C.L., Luo, S.W., Li, P.H., Zhang, L.J., Guan, Y.J., Butt, K.M., Wong, K.W., Chan, K.L., Lim, W., Shortridge, K.F., Yuen, K.Y., Peiris, J.S. and Poon, L.L. (2003) Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China. Science, 302, 276-278.

[10]   Drosten, C., Gunther, S., Preiser, W., Van der Werf, S., Brodt, H.R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A., Berger, A., Burguiere, A.M., Cinatl, J., Eickmann, M., Escriou, N., Grywna, K., Kramme, S., Manuguerra, J.C., Muller, S., Rickerts, V., Sturmer, M., Vieth, H., Klenk, D.S., Osterhaus, A.D., Schmitz, H. and Doerr, H.W. (2003) Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. The New England Journal of Medicine, 348, 1967-1976.

[11]   Kindler, E. and Thiel, V. (2016) SARS-CoV and IFN: Too Little, Too Late. Cell Host Microbe, 19, 139-141.

[12]   Yoshikawa, T., Hill, T., Li, K., Peters, C.J. and Tseng, C.T.K. (2009) Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells. Journal of Virology, 83, 3039-3048.

[13]   Channappanavar, R., Fehr, A.R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D.K. and Perlman, S. (2016) Dysregulated Type I Interferon and Inflammatory Monocytemacrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe, 19, 181-193.

[14]   Zhang, D., Tang, Z.Y., Huang, H., Zhou, G.L., Cui, C., Weng, Y.J., et al. (2019) Metabolic Regulation of Gene Expression by Histone Lactylation. Nature, 574, 475-580.

[15]   O’Neill, L.A., Kishton, R.J. and Rathmell, J. (2016) A Guide to Immunometabolism for Immunologists. Nature Reviews Immunology, 16, 553-565.

[16]   Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M., McGettrick, A.F., Goel, G., et al. (2013) Succinate Is an Inflammatory Signal That Induces IL-1β through HIF-1α. Nature, 496, 238-242.

[17]   Clement, C., Tiwari, V., Scanlan, P.M., Valyi-Nagy, T., Yue, B.Y. and Shukla, D. (2006) A Novel Role for Phagocytosis-Like Uptake in Herpes Simplex Virus Entry. Journal of Cell Biology, 174, 1009-1021.

[18]   Macintyre, A.N., Gerriets, V.A., Nichols, A.G., Michalek, R.D., Rudolph, M.C., Deoliveira, D., et al. (2014) The Glucose Transporter Glut1 is Selectively Essential for CD4 T Cell Activation and Effector Function. Cell Metabolism, 20, 61-72.

[19]   Zheng, W., Wang, G., Xu, Z-G., et al. (2019) Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS. Cell, 178, 176-189.

[20]   Lottes, R.G., Newton, D.A., Syropoulos, D.D. and Baetz, J.E. (2015) Lactate as Substrate for Mitochondrial Respiration in Alveolar Epithelial Type II Cells. The American Journal of Physiology-Lung Cellular and Molecular Physiology, 309, L953-L961.

[21]   Xie, J.C., Zhu, L.L., Luo, H.P., Zhou, L., Li, C.X. and Xu, X.J. (2001) Direct Extraction of Specific Pharmacophoric Flavonoids from Gingko Leaves Using a Molecularly Imprinted Polymer for Quercetin. Journal of Chromatography A, 934, 1-11.

[22]   Wen, C.C., et al. (2007) Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities Against Severe Acute Respiratory Syndrome Coronavirus. Journal of Medicinal Chemistry, 50, 4087-4095.

[23]   Ling, Y., et al. (2004) Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells. Journal of Virology, 78, 11334-11339.